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CGH = comparative genome hybridization; DCIS = ductal carcinoma in situ; HMEC = human mammary epithelial cell; NRT = nonreciprocal translo-




Telomeres serve as nucleoprotein caps that protect the
ends of linear eukaryotic chromosomes. They are com-
prised of nucleotide repeats (TTAGGG in mammals) and
are bound by a complex array of proteins that stabilize for-
mation of a looped and protected chromosome end [1].
This highly packaged telomere structure (t-loop) serves
two critical functions: it sequesters the chromosome end
from cellular machinery that might mistake it for a broken
chromosome and cause checkpoint activation; and it pre-
vents access of recombination enzymes that can physi-
cally join chromosomes together. In this way, intact
telomere structure is required for continued cell prolifera-
tion and viability, and is critical for maintaining chromoso-
mal stability. As cells divide in the absence of telomerase
– the enzyme that synthesizes telomere repeats – telom-
eres shorten progressively because DNA polymerase
cannot fully replicate the extreme ends of chromosomes.
In primary human fibroblasts, progressive telomere short-
ening associated with proliferation in culture leads to two
fundamentally different responses. First, after 60–80 cell
divisions fibroblasts encounter replicative senescence, a
state of permanent growth arrest and altered morphology
that requires intact p53 and Rb (retinoblastoma suscepti-
bility gene product) tumor suppressor pathways. Inactiva-
tion of both p53 and Rb with viral oncoproteins or
antisense strategies allows cells to bypass senescence
and, after extended proliferation, enter crisis. Crisis is
characterized by widespread apoptosis and chromosomal
instability as the full impact of critical telomere shortening
and chromosomal end-to-end fusions are seen [2].
Ectopic expression of telomerase reverse transcriptase
(TERT), the protein catalytic subunit of telomerase, can
reconstitute telomerase activity, lengthen telomeres, and
bypass both senescence and crisis, endowing human
fibroblasts with immortal proliferative properties [3].
Telomerase – an enzyme that endows cells with unlimited proliferative potential – is differentially
expressed in cancer cells and in normal cells. Although most primary human cells lack telomerase, the
enzyme is upregulated in more than 90% of invasive breast cancers. As a result, much of breast cancer
development occurs before telomerase is reactivated during a critical transition from a telomerase-
negative to a telomerase-positive state. During this transition, the telomere shortening that
accompanies cell division may either prevent or facilitate tumorigenesis by activating checkpoints and
impairing chromosomal stability. In mature cancers, telomerase probably serves a crucial role in tumor
progression and maintenance by stabilizing telomeres and supporting the immortal growth of breast
cancer cells.
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Human mammary epithelial cells enter crisis
after p16INK4A loss
Primary human mammary epithelial cells (HMECs) and
some other epithelial cells do not abide by this simple two-
step paradigm. HMECs experience premature growth
arrest after a much smaller number of cell divisions than is
necessary for replicative senescence. Unlike replicative
senescence, this growth arrest is not bypassed by ectopic
TERT expression, indicating that telomere shortening is
not the trigger for this arrest. Selection for HMEC clones
that escape from this arrest is associated with epigenetic
changes, including reduced p16INK4A expression, and
therefore compromise of the Rb pathway [4]. After epige-
netic silencing of p16INK4A, HMECs proliferate for an addi-
tional 30–50 population doublings before encountering a
telomere-based barrier to continued cell division. This
latter growth arrest has features of both replicative senes-
cence and crisis; HMECs exhibit a senescent morphology,
but show elevated rates of apoptosis and evidence for
chromosomal instability [5]. That this barrier is telomere-
based is evidenced by the formation of chromosome end-
to-end fusions and the observation that ectopic TERT
expression immortalizes HMECs in this phase and pre-
vents onset of growth arrest [6].
It remains unclear whether the behavior of HMECs in
arresting prematurely and entering crisis after epigenetic
loss of p16INK4A is indicative of how these cells behave in
vivo or instead reflects growth conditions in culture [5,7].
Careful analyses of growth properties of human fibroblasts
and HMECs have shown that continued proliferation after
checkpoint inactivation (via T antigen expression and
p16INK4A loss, respectively) results in eventual loss of
telomere capping function and impaired chromosomal sta-
bility. Telomeres that become so short that they can no
longer protect the chromosome end are said to be criti-
cally short or dysfunctional. Experiments in telomerase-
deficient mice have shown that such unchecked telomere
dysfunction can drive breast carcinogenesis.
Telomere-based crisis promotes mammary
carcinogenesis in telomerase-deficient mice
Telomerase is comprised of a heterodimer of TERT and
telomerase RNA component (TERC), a required RNA
encoding the telomere sequence that is reverse tran-
scribed during telomere synthesis. Inactivation of mouse
TERC (mTERC) via homologous recombination in embry-
onic stem cells resulted in viable mTERC–/– mice that
lacked telomerase activity, but were phenotypically normal
because they retained long telomeres [8]. Telomeres in
mice are much longer than telomeres in humans
(40–60 kb versus 5–15 kb). By interbreeding mTERC–/–
mice for multiple generations, telomeres shortened pro-
gressively and became critically short in generations four
to six. In these late generations, mTERC–/– mice became
infertile and showed proliferative defects and increased
apoptosis in organ systems with high turnover [9]. These
defects in cell proliferation and survival occur when telom-
ere uncapping triggers activation of the tumor suppressor
p53, which responds to a variety of cellular stresses,
including DNA damage, oncogene activation, and hypoxia.
Loss of p53 in late-generation mTERC–/– mice blunted the
apoptotic response to telomere dysfunction and improved
cell survival [10]. Thus, the integrity of the p53 checkpoint
is a crucial determinant of the cellular response to telom-
ere dysfunction. Late-generation telomerase-deficient
mice can serve as a useful in vivo model to explore the
impact of telomere attrition on tumorigenesis.
Late-generation mTERC–/– mice with intact p53 pathways
are highly tumor resistant, which is consistent with predic-
tions based on observations of senescence/crisis
responses in primary human cells that telomere shortening
would suppress tumorigenesis. Telomere uncapping in
late-generation mTERC–/– p53+/+ mice resulted in
impaired tumor formation when these mice were treated
with chemical carcinogens [11], or studied on an
INK4A–/– [12] or APC+/– [13] tumor-prone background.
To determine the impact of dysfunctional telomeres
unchecked by p53 activation on tumorigenesis in vivo,
compound mTERC–/– p53-deficient mice were generated
and monitored for spontaneous tumor development. In
contrast to the models with intact p53-dependent DNA
damage response pathways, telomere uncapping in late-
generation mTERC–/– p53–/– or p53+/– mice significantly
accelerated the rate of tumor formation [14]. In addition to
accelerating tumorigenesis, telomere dysfunction dramati-
cally altered the spectrum of tumor types in p53+/– mice.
Whereas p53+/– mice with intact telomeres developed
predominantly lymphomas and sarcomas, late-generation
mTERC–/– p53+/– mice succumbed primarily to epithelial
cancers, including carcinomas of the breast, skin, and
gastrointestinal tract. Therefore, telomere-based crisis (i.e.
telomere shortening that proceeds unchecked by p53
activation) can promote spontaneous transformation in
mammary tissue and other epithelial compartments.
Telomere dysfunction, translocations and
copy number changes
To determine the mechanism by which unchecked telomere
uncapping caused murine breast cancers, chromosome
structure was analyzed in breast carcinomas from late-
generation mTERC–/– p53+/– mice. Spectral karyotype
analysis revealed that telomere shortening promoted for-
mation of translocations between nonhomologous chromo-
somes. These translocations were of the nonreciprocal
type and were not seen in cancers from p53-deficient mice
with long telomeres [14]. Unlike classical balanced translo-
cations, nonreciprocal translocations (NRTs) lead to copy
number changes in the involved chromosomal regions.
Comparative genome hybridization (CGH) analysis of
breast cancers and other carcinomas from late-generation39
mTERC–/– p53+/– mice revealed widespread regions of
amplification or deletion, significantly altering gene copy
number [15]. These regions presumably harbor important
oncogenes and tumor suppressor genes. Dysfunctional
telomeres promote these genomic alterations through
cycles of chromosomal fusion–bridge–breakage. Telom-
ere uncapping results in exposure of the chromosome end
to recombination machinery, generating an end-to-end
fusion. The presence of two centromeres renders these
dicentric chromosomes unstable, because each cen-
tromere can attach to opposite poles of the mitotic spindle
during mitosis. The dicentric chromosome is stretched
and broken during anaphase, and these broken chromo-
somes can generate NRTs or a new dicentric chromo-
some, which can fuel another round of fusion–bridge–
breakage. Therefore unrestricted telomere dysfunction in
p53-deficient cells promotes cancer in part by generating
NRTs and widespread gene copy number changes.
Genomic alterations and telomere dynamics
in human breast cancer
These genomic alterations seen in breast cancers driven
by telomere dysfunction closely resemble those seen in
human breast cancers. Human breast cancers, as well as
other carcinomas, harbor NRTs and gene copy number
changes. Both known oncogenes and novel oncogenes
have been identified in regions of amplification identified
by CGH. Chromosomes become destabilized very early in
human breast cancer development. Copy number
changes are evident in usual ductal hyperplasia and atypi-
cal ductal hyperplasia by CGH [16,17]. These aberrations
become more abundant by the ductal carcinoma in situ
(DCIS) stage, but then appear similar in number in inva-
sive breast cancers. In fact, these clonal gene copy
number changes are shared to a large extent among
DCIS, invasive cancer, and metastatic lesions in the same
patient [18,19]. These data suggest that chromosomal
instability is impaired early in tumorigenesis, but only tem-
porarily because the genome appears much more stable
during progression. How the breast cancer genome
becomes destabilized early in tumorigenesis and then
restabilized after the DCIS stage remains unknown. One
possible explanation is that incipient cancers, dividing
before telomerase reactivation, sustain significant telom-
ere shortening and circumvent the p53 checkpoint,
leading to cycles of chromosomal fusion–bridge–break-
age that fuel chromosomal instability and carcinogenesis
(Fig. 1). In support of this hypothesis, telomeres shorten
during carcinogenesis and then become stabilized at a
shorter length in invasive breast cancers [20].
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Figure 1
Telomere dynamics and chromosomal instability during human breast cancer development. Telomeres shorten during human tumorigenesis (gray
line) and then become stabilized at the ductal carcinoma in situ (DCIS) or invasive stage. Telomerase is expressed at low or undetectable levels in
normal cells, but becomes activated in 80–90% of DCIS lesions and remains highly active in invasive and metastatic breast cancers (dotted black
line). Comparative genome hybridization analyses have shown that chromosomal imbalances or gene copy number changes begin early in breast
cancer, in usual ductal hyperplasia and atypical ductal hyperplasia. Copy number aberrations increase in DCIS and remain similar in number in
invasive cancer and metastatic cancer. Chromosomal instability (dashed black line) therefore begins in usual ductal hyperplasia and increases
through DCIS development. The rate of accumulation of chromosomal aberrations slows significantly at the DCIS stage and this stabilization of the


















Although most human breast cancers may harbor chromo-
somal rearrangements, not all of these cancers contain
p53 mutations. In fact, only approximately 30% human
breast cancers have shown p53 mutations, suggesting
that gene copy number changes can accumulate in p53
wild-type cancer cells. These data suggest that mutations
in other components of the p53 pathway, or in separate
pathways that control DNA damage checkpoints, may
create a permissive environment for chromosomal
rearrangements. Further work will be necessary to deter-
mine what role telomere dysfunction plays in formation of
chromosomal rearrangements in human breast cancer and
what other mechanisms might contribute to destabilizing
the breast cancer genome.
Two distinct roles for telomerase reactivation
in cancer
Whereas normal mammary tissue lacks significant telom-
erase activity, telomerase is expressed in 80–90% of
DCIS lesions and in 90% of invasive breast cancers [21].
Telomerase reactivation therefore coincides temporally
with the relative stabilization of the cancer genome. If
telomere dysfunction aids in formation of genomic
rearrangements that facilitate cancer formation, then
telomerase reactivation later in the course of carcinogene-
sis probably favors tumor progression. Re-establishing
telomere maintenance is probably necessary to stabilize
telomeres, to ‘lock in’ genomic alterations that are neces-
sary for tumorigenesis, and to allow significant clonal
expansion. Can telomerase reactivation serve other func-
tions beyond re-establishing telomere maintenance?
Experiments designed to address this question have
yielded mixed results. In primary human fibroblasts and
retinal pigment epithelial cells, telomerase reconstitution
led to immortal proliferation but did not alter normal regula-
tory and checkpoint circuits [22,23]. In contrast, ectopic
expression of telomerase in HMECs that have epigeneti-
cally silenced p16INK4A resulted in decreased sensitivity to
the inhibitory effects of transforming growth factor-β [24].
Transgenic models of TERT overexpression in wild-type
mice with long telomeres suggest that telomerase can
encourage neoplastic growth even in the absence of criti-
cally short telomeres. Expression of TERT in a broad
variety of mouse tissues resulted in spontaneous breast
cancers at long latency [25]. Directing TERT expression to
mouse keratinocytes rendered them more sensitive to the
transforming effects of chemical carcinogens [26]. These
data suggest that telomerase may have two functions: one
in stabilizing short telomeres and averting the deleterious
consequences of telomere dysfunction for proliferation
and survival; and a second activity that promotes prolifera-
tion independent of telomere length.
Conclusion
Primary human fibroblasts and HMECs in culture readily
enter telomere-based crisis when p53 and/or Rb check-
points are impaired. The chromosomal instability associ-
ated with unchecked telomere dysfunction can drive
breast carcinogenesis in vivo in telomerase-deficient mice,
suggesting that telomere-based crisis in humans may simi-
larly enhance rates of epithelial tumorigenesis. This mech-
anism may underlie the formation of common
chromosomal aberrations and copy number changes seen
in human breast cancers. Telomerase reactivation serves
to restore telomere function, reduce chromosomal instabil-
ity, and promote tumor maturation. Emerging evidence
indicates that telomerase probably serves additional func-
tions in promoting tumorigenesis. Telomerase inhibition
remains a promising target for pharmacologic inhibition in
the treatment of human malignancies.
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